Last reviewed · How we verify
Market-approved OAC — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Market-approved OAC (Market-approved OAC) — Boston Scientific Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Market-approved OAC TARGET | Market-approved OAC | Boston Scientific Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Market-approved OAC CI watch — RSS
- Market-approved OAC CI watch — Atom
- Market-approved OAC CI watch — JSON
- Market-approved OAC alone — RSS
Cite this brief
Drug Landscape (2026). Market-approved OAC — Competitive Intelligence Brief. https://druglandscape.com/ci/market-approved-oac. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab